4591 Ribomic
- 94
- -2-2.08%
Ribomic News
Ribomic: Extraordinary Report
Ribomic: Confirmation Letter
Ribomic: Securities Report - 21st period (April 1st, 2023 - March 31st, 2024)
RIBOMIC: Financial Results Briefing for the Fiscal Year Ending March 31, 2024 (Q&A)
RIBOMIC: Financial results briefing materials for the fiscal year ending 2024/3
Ribomic Sees FY Loss Y1.41B
RIBOMIC: Summary of Financial Results for the Fiscal Year Ending March 31, 2024 [Japanese GAAP] (unconsolidated)
Brands that moved the day before part 2 PLANT, Sumiseki HD, Regil, etc.
<コード>Stock name closing price on the 24th ⇒ revised downward to the final major deficit due to Ahresty ＜5852＞ 647 -129 impairment recording compared to the previous day. Disgusted with potential dilution due to the issuance of Resonac ＜4004＞ 3390 -321CB. Profitable sales from fund shifts in the high price range of Hokkaido Electric Power ＜9509＞ 1155.5 -82.5. Orbic ＜4684＞ The rate of increase in sales for the fiscal year ending 20035 -16351-3 fell to the 1-digit range. Strike ＜6196＞ 4445 -365
Emerging Market Stock Digest: GENDA continues to rise drastically for 3 days, and Linkers stops high
＜4586＞ Medlec 118 +2 repulsion. The operating profit and loss forecast for the fiscal year ending 24/12 has been revised upward from the previous deficit of 1,425 billion yen to a deficit of 1,183 billion yen (deficit of 933 million yen in the previous fiscal year results). Favorable pharmacokinetics and tolerability were shown in clinical phase 1 trials of the new drug candidate “Alto-101” in the central nervous system area, development milestones stipulated in a partnership agreement with the US drug discovery venture Alto have been achieved, and milestone revenue and paid clinical trial drug supply are expected
Front market [stocks that have moved, stocks that have been created]
*Nomura Micro Science ＜6254＞ I like the upward revisions to 5460 +705 earnings and dividend forecasts. *KOA ＜6999＞ 1597 +172 look positively at the 2-digit profit increase forecast for the current fiscal year. *Nikon ＜7731＞ 1731 +167.5 Silchester became the majority shareholder of over 5%. *Komeri ＜8218＞ 3745 +335 to evaluate favorable earnings forecasts for the current fiscal year, stock buybacks, etc. *Renesas Electronics＜6723＞ 2498.5 +217.5 US T
Featured Stock Digest (front field): Nomura Micro, Ahresty, Linkers, etc.
A sharp decline. Financial results for the fiscal year ending 24/3 were announced the day before. Operating profit was 70.9 billion yen, up 13.5% from the previous fiscal year, which slightly exceeded the previous forecast of 70 billion yen.
Ribomic---Continued significant growth for 3 days, developed a new PEG replacement technology, and completed a patent application
A significant increase of 3 days. It has been announced to the Japanese Patent Office that a patent application relating to a conjugate (complex formation by chemical bonding) between aptamer and polyethyloxazoline and extending its half-life in blood has been completed. It was discovered that the conjugate of aptamer and polyethyloxazoline shows excellent internal dynamics and is an alternative compound for polyethylene glycol (PEG). Quality control of compounds is easy, and it is expected that they will be supplied at low cost in the future.
Ewell, AB & Company, etc.
＜175A＞Wild Smart Co., Ltd. Ishii Yasuhiro Stock Ownership Ratio -% → 6.66% Reporting Obligation Date 2024/04/16 ＜175A＞Will Smart Co., Ltd. Zenrin Stock Ownership Ratio -% → 44.67% Reporting Obligation Occurrence Date 2024/04/16 ＜4563＞Angers Co., Ltd. Canter Fitzgerald Europe (Cantor Fitzgerald Europe) Stock Certificates
Innovation, Anges, etc.
＜3970＞Innovation 7th Stock Acquisition Rights (with exercise price amendment clause) number of shares issued from 8th, 33,900 shares ＜4563＞number of shares issued from mass exercise 8th of Anges 1st Unsecured Convertible Bonds (with convertible price correction clauses), 3.55 million 1912 shares ＜4591 ＞Additional support adopted based on high evaluation of the “AI Aptamer Drug Discovery Project”
Soracom, Hatch Work, etc.
＜147A＞Soracom Will Management Co., Ltd. (WiL MANAGEMENT III, LLC) Stock Ownership Ratio -% → 7.55% Reporting Obligation Date 2024/03/26 ＜147A＞Soracom Co., Ltd. Daichi Funato Stock Ownership Ratio -% → 7.57% Reporting Obligation Date 2024/03/26 ＜147A＞Soracom Co., Ltd. Tamagawa Ken Stock Ownership Ratio -% → 7.65%
Ribomic Sees Parent FY Loss Y1.25B
Ribomic Enters Into Drug Research Collaboration With Ajinomoto
RIBOMIC Phase I and II Data Published in the Eye: Full TOFU/RAMEN/TEMPURA Trial Results Demonstrate Clinical Proof of Concept of Umedaptanib Pegol in Exudative Age-Related Macular Degeneration (NAMD)
Ribomic 1H Parent Loss Y554.00M Vs Loss Y878.00M
Ribomic Sees FY Loss Y1.25B
Analysis
Price Target
No Data
